dofequidar has been researched along with B16 Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, H; Baba, M; Fukazawa, N; Naito, M; Nakanishi, O; Saito, A; Sato, S; Sato, W; Suzuki, T; Tsuruo, T; Yamashita, T | 1 |
| Aoki, J; Kimura, Y; Kohno, M; Nakanishi, O; Ooka, H; Tsuruo, T | 1 |
2 other study(ies) available for dofequidar and B16 Melanoma
| Article | Year |
|---|---|
Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Colorectal Neoplasms; Doxorubicin; Drug Resistance, Multiple; Drug Synergism; Female; Humans; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Quinolines; Stomach Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured; Vincristine | 1997 |
P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Cyclosporine; Cyclosporins; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Paclitaxel; Quinolines; Rats; Rats, Sprague-Dawley | 2002 |